Published in final edited form as:

Int J STD AIDS. 2018 March ; 29(4): 324–333. doi:10.1177/0956462417724908.

High prevalence of asymptomatic sexually transmitted infections among human immunodeficiency virus-infected pregnant women in a low-income South African community

Maanda Mudau¹, Remco P Peters^{2,3}, Lindsey De Vos¹, Dawie H Olivier¹, Dvora J Davey^{4,5,6}, Edwin S Mkwazazi¹, James A McIntyre^{2,7}, Jeffrey D Klausner^{5,6}, Andrew Medina-Marino¹

¹Research Unit, Foundation for Professional Development, Pretoria, South Africa

²Anova Health Institute, Johannesburg, South Africa

³Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

⁴Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

⁵David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

⁶Department of Epidemiology, University of California Los Angeles, Los Angeles, CA, USA

⁷School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Abstract

There is a lack of evidence on the burden of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG) and *Trichomonas vaginalis* (TV) among HIV-infected pregnant women in South Africa. We conducted a cross-sectional analysis of HIV-infected pregnant women in two healthcare facilities in a South African township to determine the prevalence of CT, NG and TV. HIV-infected pregnant women were recruited during the first antenatal care visit for their current pregnancy and requested to self-collect vulvovaginal swab specimens. Specimens were tested for CT, NG and TV using the Xpert® assay (Cepheid, Sunnyvale, CA). Of 247 tested for CT, NG and TV, 47.8% tested positive for at least one organism; CT = 36.8%, TV = 23.9%, NG = 6.9%. Forty three (17.4%) had multiple infections, of which 42 included CT as one of the infecting organisms. Of the 118 participants who tested positive for at least one sexually transmitted infection (STI), 23.7% reported STI-like symptoms. Among women who tested positive for CT, 29.7% reported

Reprints and permissions: sagepub.co.uk/journalsPermissions.nav

Corresponding author: Andrew Medina-Marino, Foundation for Professional Development, 173 Mary Road, Die Wilgers, Pretoria, ZA 0184, South Africa. andrewmedinamarino@gmail.com.

Authors' contributions

AM-M and JDK conceived the study and are the primary grant holders. MM, RPP, LDV, DO, DJD and JAM contributed to the design of the study. LDV, DO and EM managed the implementation of the study and oversaw data collection. MM, EM, DJD and RPP conducted data analysis. MM drafted the manuscript. All authors assisted with interpretation of results, commented on draft versions and approved the final version of the manuscript.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

symptoms while 47.1 and 27.1% of those who tested positive for NG and TV, respectively, reported symptoms. The high STI prevalence coupled with the low symptom prevalence among infected individuals justifies the use of diagnostic screening approaches rather than syndromic management of STIs in this setting.

Keywords

Chlamydia; gonorrhoea; HIV; screening; trichomoniasis

Introduction

Chlamydia trachomatis (CT), *Neisseria gonorrhoeae* (NG) and *Trichomonas vaginalis* (TV) are major contributors to the global burden of disease. According to the most recent World Health Organization (WHO) estimates, more than 90 million new cases of these three infections were reported among adults aged between 15 and 49 years in Africa in 2008.¹ TV alone accounted for approximately 59.7 million of those cases, while CT and NG account for 8.3 and 21.1 million cases, respectively.

Numerous studies have shown that these sexually transmitted infections (STIs) significantly increase the risk for HIV transmission and acquisition. CT, NG and TV lead to inflammatory cytokine upregulation with subsequent accumulation of leukocytes – some of which are HIV target cells – in tissues around the genital tract as part of the immune response, which further increases the risk of HIV acquisition.^{2–4} The inflammatory response may be present even without apparent signs and symptoms.⁵ Lesions that result from these STIs facilitate virus shedding, which increases the risk of genital HIV transmission to sexual partners during sexual intercourse.

During pregnancy, untreated STIs may lead to a variety of complications including intrauterine death (spontaneous abortion), preterm delivery, intrauterine growth retardation and low birth weight.^{6–8} Recently published evidence suggests that these STIs may increase the risk of mother-to-child transmission (MTCT) of HIV.^{9,10} Analysis of data from a multi-site study demonstrated that the rate of HIV MTCT was higher among infants born to mothers infected with CT (10.7%) or both CT and NG (14.3%) compared to those born to uninfected mothers (8.1%).⁹ This finding was in line with a previous study conducted in Tanzania, which found that HIV-infected pregnant women with NG infection had 5.5 times increased risk of intrauterine transmission of HIV.¹⁰

There is a lack of data on the prevalence of CT, NG and TV among pregnant women and their associated risk factors; especially in sub-Saharan Africa, which bears a disproportionate burden of HIV. The lack of epidemiological data impedes efforts to develop guidelines to effectively control these STIs. The few studies that have been published have reported infection rates among pregnant women, which are substantially higher than the general population.^{9–11}

Despite compelling evidence from other regions supporting the establishment of universal diagnostic screening of CT, NG and TV in pregnancy with molecular tests, the majority of

countries in Africa and other low-resource settings rely on the WHO-recommended syndromic approach in which treatment of STIs is based on the presence of defined signs and symptoms.¹¹ Given that most CT, NG and TV infections are asymptomatic, many infected women remain untreated.¹² Consequently, the syndromic approach is ineffective in controlling those infections or reducing associated adverse pregnancy outcomes.¹³

We conducted a cross-sectional analysis of HIV-infected pregnant women accessing antenatal care (ANC) services at two primary healthcare (PHC) facilities in a South African township to determine the prevalence of CT, NG and TV. We also sought to determine the prevalence of symptoms among participants in order to inform recommendations relating to diagnosis and management of STIs during pregnancy.

Methods

Study design

This study was a cross-sectional analysis of women recruited as part of a study that sought to determine the acceptability and feasibility of using a point-of-care test for STI screening among HIV-infected pregnant women, conducted from 1 June 2016 to 31 October 2017. The current analysis included data from participants recruited up to 24 March 2017. The South African STI Treatment Guidelines recommend syndromic management of STIs in PHC facilities.¹⁴ In this study, a point-of-care nucleic acid amplification test was incorporated into the basic ANC package offered to women at their first antenatal visit.

Study setting

The study was conducted at two PHC facilities in Tshwane District, South Africa; Tshwane incorporates Pretoria, the administrative capital of South Africa. Tshwane's estimated general population HIV prevalence is 11.7% (95% CI: 8.1–16.6%).¹⁵ Among pregnant women using ANC services in Tshwane, the estimated HIV prevalence is 23.4% (95% CI: 20.1–27.1%).¹⁶ In 2014, early infant (six weeks) HIV positivity was estimated to be 1.85%.¹⁷

Recruitment and data collection

The eligibility criteria for the main study were used in this analysis and included (1) women attending their first ANC session for their current pregnancy; (2) documented HIV-positive status; (3) gestational age less than 35 weeks; (4) age ≥ 18 years; (5) currently reside in Tshwane District, with intent to remain in Tshwane following delivery. Women were screened for eligibility by a research assistant. Gestational age was estimated via a gestational wheel using the last known menstruation date, with clinical confirmation via palpation and symphysis measurements by a study nurse. Eligible women providing consent were assigned a unique participant identification number (PIN).

Participants were interviewed by a research assistant using a structured questionnaire, which included socio-demographic characteristics and STI symptom screening questions. After being interviewed, a research nurse provided Basic Antenatal Care services as per South African Maternity Care Guidelines.¹⁸ During this process, the research nurse collected

clinical data including obstetric history, co-morbidities and HIV antiretroviral therapy. A physical vaginal examination was performed to assess for STI-defining signs and symptoms. The exterior of the vagina and vulva was inspected for any abnormalities or signs of infection including ulcers, lice, sores, scarring or warts, and for discharge (colour, odour, thickness and purulence). Where necessary, digits or a speculum was used in the vaginal orifice to inspect for any abnormalities, or for cervical position, effacement, thickness or pain.

Specimen collection and testing

Participants self-collected two vulvovaginal swab specimens using Xpert® CT/NG Vaginal/Endocervical Specimen Collection kits (Cepheid, Sunnyvale, CA) as per manufacturer instructions. Specimens were tested immediately and women were given results, and treatment if indicated, prior to leaving the facility. CT and NG were tested using the Xpert® CT/NG assay and TV was tested using the Xpert® TV assay (Cepheid, Sunnyvale, CA). Tests were conducted by clinic research staff. Participants were given targeted treatment on the basis of the Xpert® result if positive or treated syndromically if negative for all three organisms on Xpert®. As per South African STI guidelines Xpert®-positive participants were given partner notification/referral slips; these participants were also given the option to take a partner treatment packet with them for their sexual partner(s) for expedited treatment, which was not part of routine care. Participants were advised to return unused or leftover partner medication when visiting facilities for their STI test of cure.

Data management and analysis

Real-time data collection, using REDCap (Research Electronic Data Capture), was performed on tablet computers.¹⁹ All captured data were stored in a secure, password-protected web-based server. Data quality checks were performed regularly, and inconsistencies were flagged for verification and correction. Barcoded PINs were placed on consent forms, copies of source documents, specimen collection containers and test cartridges to allow for direct linkage of participant data.

Prevalence was defined as the proportion of individuals who tested positive among individuals who were tested. Normality was assessed graphically and by the Shapiro-Wilk test; normally distributed variables were compared using Student's t-test, and non-normally distributed variables were analysed using Mann-Whitney U test. Categorical variables (proportions) were compared using the Chi square test (χ^2) or its non-parametric equivalent. Univariate and multivariate logistic regression were used to calculate odds ratios (OR) and their 95% confidence intervals (CI) to determine factors associated with being symptomatic among infected individuals. Multivariate logistic regression was conducted using the stepwise backward-elimination method (p-removal > 0.05). Variables significantly associated with being symptomatic at $p < 0.25$ in univariate logistic regression were included in the multivariate analysis. All data analyses were done in STATA v13 (StataCorp. 2013, College Station, Texas).

Ethical considerations

Permission to conduct the study was obtained from the management of our two study clinics and the Tshwane District Research Committee. Ethical clearance was obtained from the University of Pretoria, Faculty of Health Sciences, Research Ethics Committee (Ref: 401/2015) and the University of California Los Angeles (Ref: 15-001351). The ethics committees also gave permission for expedited partner therapy. Written informed consent was sought from all participants before they were enrolled into the study.

Results

Population characteristics

A total of 263 HIV-infected ANC attendees were screened for eligibility, of whom 251 (93.5%) were eligible, and 247 (98.4%) were enrolled into the study. The median age of participants was 30 years (IQR = 26–34 years). Ninety-eight per cent of participants were black African and 56.1% had not completed high school education. Though only 15.9% of participants were married, 33.3% lived with the father of their baby but were not married; 2.4% reported no relationship with the father of the baby. Close to sixty per cent (59.3%) reported that they were unemployed and 39.8% had a personal monthly income below 1000 ZAR (approximately 70 USD) or no income at all. Median gestational age at first ANC was 17 weeks (IQR: 13–23) (Table 1).

STI prevalence

Participants (n = 247) were tested for all three organisms, of whom 47.8% (n = 118) tested positive for at least one STI; CT = 36.8% (n = 91), TV = 23.9% (n = 59), NG = 6.9% (n = 17). Seventy-five women (30.4%) had mono-infections, and 17.4% (n = 43) had multiple infections (Table 2). Forty-two (97.7%) of the 43 multiple infections included chlamydia as one of the infecting microorganisms (Figure 1). All infected women received their results and medication for their infection before leaving the healthcare facility on the day of the test.

Prevalence varied by socio-demographic and clinical characteristics (Table 3). STI prevalence among pregnant women younger than 25 years (66.7%; 95% CI: 51.0–79.3%) was significantly higher than pregnant women aged 25–35 years (43.5%; 95% CI: 36.1–51.1%), but not significantly higher than pregnant women >35 years (45.9%; 95% CI: 30.6–62.2%). Overall prevalence was significantly higher among pregnant women who reported that they had a steady partner who did not live with them (55.9%; 95% CI: 46.8–64.7%) compared to those who reported that they were married (28.2%; 95% CI: 16.2–44.4%). There were no significant differences in prevalence by other demographic characteristics. There were also no significant differences in prevalence of STIs by clinical characteristics; however, it is notable that prevalence was highest among women attending their first ANC visit during their third trimester of pregnancy (57.1%; 95% CI: 35.4–75.6%), compared to women in earlier trimesters. Primigravidae also had the highest prevalence (58.6%; 95% CI: 39.9–75.1%), in comparison to multigravidae. Pregnant women with detectable HIV viral loads (>50 copies/ml) had a higher prevalence of STIs (54.8%; 95% CI: 42.2–66.9%), compared to those with undetectable viral loads (38.2%; 95% CI: 23.3–55.8%).

Prevalence of symptoms among STI-infected individuals

Overall, 23.9% (n = 59) of the women recruited into the study reported that they experienced at least one of the following symptoms in the seven days prior to being tested: abnormal vaginal discharge, pain during sexual intercourse, pain during urination or vaginal bleeding. There was no significant difference in the prevalence of symptoms by STI status (p = 0.956). Among women who tested negative for all three STIs, 24% (31/129) reported symptoms. Of the 118 participants who tested positive for at least one STI, 23.7% (28/118) reported symptoms. This varied by micro-organism. Among women who tested positive for CT, 29.7% (27/91) reported symptoms while 47.1% (8/17) and 27.1% (16/59) of those who tested positive for NG and TV, respectively, reported symptoms. When examined by a nurse 31.4% (n = 37) of participants who tested positive for STIs had visible STI-related signs (abnormal vaginal discharge or vaginal bleeding). This also varied by micro-organism with 31.9% (29/91) of CT-positive women having signs while 52.9% (9/17) of those infected with NG and 37.3% (22/59) of those infected with TV having signs. By combining self-reported symptoms and nurse examination, 41.5% (n = 49) were symptomatic (Table 4). In multivariate analysis, factors independently associated with being symptomatic (combined self-report and nurse examination) were age <25 years (OR = 6.01; 95% CI: 1.86–19.4) and first trimester of pregnancy (OR 0.24; 95% CI: 0.07–0.86) (Table 5).

Discussion

To the best of our knowledge, this is only the second study to use a point-of-care molecular diagnostic test to determine prevalence of CT, NG and TV among HIV-infected pregnant women in an African setting. Our study has documented high prevalence of three curable STIs in a population of HIV-infected pregnant women. Nearly 50% of HIV-positive pregnant women in our study sample tested positive for CT, NG and/or TV. The prevalence of CT in our study population is considerably higher than rates reported before among pregnant women in South Africa. In a systematic review that sought to summarise prevalence of curable STIs among pregnant women, Joseph Davey et al.²⁰ reported an adjusted mean prevalence of 4.4% (95% CI: 2.3–6.6%) for CT, 4.6% (95% CI: 4.0–5.2%) for NG and 24.6% (95% CI: 17.9–31.4%) for TV in the Southern African region. In a multi-site study, Adachi et al.⁸ reported a CT prevalence of 21.3% among HIV-infected women in South Africa. Another study, conducted among women visiting a termination of pregnancy clinic, reported an aggregate prevalence of CT, NG and TV of 27%, with a CT-specific prevalence of 14%.²¹ Another study, conducted in KwaZulu-Natal province, South Africa, reported CT prevalence of 17.8% (95% CI: 15.8–19.7%), NG prevalence of 6.4% (95% CI: 5.1–7.6%) and TV prevalence of 15.3% (95% CI: 13.5–17.2%) among pregnant women.²²

To our knowledge, our finding of a 36.8% (95% CI: 31–43.1%) prevalence of CT in pregnant women is the highest reported in pregnant women, globally. A possible reason for this higher prevalence is that our study sample consisted exclusively of HIV-infected women – who may be at higher risk of STIs. Unpublished data from our study sample show high levels of sexual risk behaviours including high levels of condomless sex at last sex and having multiple sexual partners in the past 12 months.²³ It should also be noted that the diagnostic assay used in our study is not identical to those used in other studies and there

may be disparities in test sensitivity and specificity. Nonetheless, an investigation of drivers of STIs, particularly CT, in this setting is warranted.

Although several studies have shown that HIV-infected individuals are at higher risk of STIs than HIV-uninfected individuals, available evidence suggests CT prevalence does not vary by HIV status.^{3,4,24} Moodley et al.²² found statistically significant differences in NG and TV prevalence between HIV-infected and HIV-uninfected pregnant women; however, they found no difference in CT prevalence by HIV status. Interestingly, Mafokwane and Samie²⁵ reported a CT prevalence difference between HIV-infected individuals taking ARVs and those not taking ARVs (28.5% versus 38.1%). In our study, prevalence of CT was higher among individuals with detectable viral loads compared to those with undetectable viral loads, but there seemed to be no relationship with CD4 cell count, which is a marker for immune status.

Over a third of women in our study with an STI were found to have multiple infections. The significance of multi-infections is mostly unknown; however, they complicate empirical treatment, which forms the basis of syndromic management of STIs.^{26,27} Prevalence of different combinations of organisms in those with multiple infections tends to vary by location, socio-demographic and clinical characteristics, and seems to be dependent on the prevalence of individual microorganisms.^{28–30} This highlights the need for targeted treatment based on diagnostic tests. Alternatively, granular context-specific prevalence estimates from sentinel laboratory surveillance activities can guide standardised or epidemiological treatment. Future studies need to investigate the impact of multiple infections on pregnancy outcomes in comparison with mono-infections.

Our finding that pregnant women younger than 25 years have higher STI prevalence compared to women older than 35 years confirms findings from several other studies that reported younger maternal age as a risk factor for STIs.^{31,32} There are a variety of biological, immunological and behavioural factors that contribute to this increased risk. The trend towards a higher prevalence of STIs among HIV-infected women presenting late for their first ANC consultation, although not statistically significant, is concerning. HIV-infected women who start attending ANC later in pregnancy will have less time to achieve viral suppression if they had not started antiretroviral therapy prior to this. Though viral load is the most important determinant of HIV vertical transmission,³³ STIs are known to increase vaginal shedding of HIV, thus increasing the risk of transmission from mother to child.⁹ This highlights the need for early enrolment into ANC.

Consistent with findings from other studies, the majority of women in our study with STIs were asymptomatic.^{21,22} Self-reported symptoms only identified a quarter of women with STIs, while clinician-observed symptoms could only identify about a third. Though the sensitivity of symptom screening seemed enhanced when self-reported and clinician-observed symptoms were combined, less than half of women with STI infections would have been correctly identified using this combined screening method. These results must be interpreted with caution, as symptoms may be due to infections by micro-organisms that were never tested.

The high prevalence of STIs in HIV-infected pregnant women, and the low sensitivity of symptom screening in identifying those infected with STIs, suggests that universal testing of STIs using definitive diagnostic tests may be justified in this population. Cost–benefit analyses of implementation of these diagnostic tests need to be conducted, including studies to investigate optimal models of delivery. Given reported high rates of late presentation for ANC¹⁷ and loss-to-follow up from care between the first ANC visit and delivery,³⁴ we believe that point-of-care implementation of these diagnostic platforms, followed by same-day treatment provision, would be beneficial. Finally, efforts must be made to identify drivers of STIs in the general population to aid the design of appropriate interventions.

Acknowledgements

The authors would like to acknowledge the Tshwane District Department of Health and clinic managers who gave permission to conduct the study at the respective sites and the facility staff who accommodated our study teams. We would also like to thank Collin Price and Erika Morikawa for their support in the study.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this research has been supported by the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) under award number: R21HD084274-01A1 and the President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development under the terms of the Cooperative Agreement AID 674-A-12-00017.

References

1. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One* 2015; 10: e0143304. [PubMed: 26646541]
2. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis* 1992; 19: 61–77. [PubMed: 1595015]
3. Masson L, Mlisana K, Little F, et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. *Sex Transm Infect* 2014; 90: 580–587. [PubMed: 25107710]
4. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. *Lancet* 1998; 351: 5–7.
5. Levine WC, Pope V, Bhoomkar A, et al. Increase in endocervical CD4 lymphocytes among women with non-ulcerative sexually transmitted diseases. *J Infect Dis* 1998; 177: 167–174. [PubMed: 9419184]
6. Adachi K, Nielsen-Saines K and Klausner JD. *Chlamydia trachomatis* infection in pregnancy: the global challenge of preventing adverse pregnancy and infant outcomes in sub-Saharan Africa and Asia. *Biomed Res Int* 2016; 2016: 9315757. [PubMed: 27144177]
7. Baud D, Regan L and Greub G. Emerging role of Chlamydia and Chlamydia-like organisms in adverse pregnancy outcomes. *Curr Opin Infect Dis* 2008; 21: 70–76. [PubMed: 18192789]
8. Adachi K, Klausner JD, Xu J, et al. *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in HIV-infected pregnant women and adverse infant outcomes. *Pediatr Infect Dis J* 2016; 35: 894–900. [PubMed: 27164464]
9. Adachi K, Klausner JD, Bristow CC, et al. Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV transmission. *Sex Transm Dis* 2015; 42: 554–565. [PubMed: 26372927]
10. Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. *AIDS* 2001; 15: 1157–1165. [PubMed: 11416718]

11. Medline A, Joseph Davey D and Klausner JD. Lost opportunity to save newborn lives: variable national antenatal screening policies for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. Int J STD AIDS 2017; 28: 660–666. [PubMed: 27440873]
12. White RG, Moodley P, McGrath N, et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect 2008; 84: 528–534. [PubMed: 18708485]
13. Sangani P, Rutherford G and Wilkinson D. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2004; 2: CD001220.
14. Department of Health, Republic of South Africa. Sexually transmitted infections management guidelines 2015. Pretoria: National Department of Health, 2015.
15. Shisana ORT, Simbayi LC, Zuma K, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town: HSRC Press, 2014.
16. Department of Health, Republic of South Africa. The national antenatal sentinel HIV prevalence survey, South Africa, 2013. Pretoria: National Department of Health, 2015.
17. Massyn NPN, English R, Padarath A, et al. (eds) District health barometer 2015/16. Durban: Health Systems Trust, 2015.
18. Department of Health, Republic of South Africa. Guidelines for maternity care in South Africa: A manual for clinics, community health centres and district hospitals, 2015. Pretoria: National Department of Health, 2015.
19. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381. [PubMed: 18929686]
20. Joseph Davey DL, Shull HI, Billings JD, et al. Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015: a systematic review. Sex Transm Dis 2016; 43: 450–458.
21. De Jongh M, Lekalakala MR, Le Roux M, et al. Risk of having a sexually transmitted infection in women presenting at a termination of pregnancy clinic in Pretoria, South Africa. J Obstet Gynaecol 2010; 30: 480–483. [PubMed: 20604651]
22. Moodley D, Moodley P, Sebitloane M, et al. High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in KwaZulu Natal, South Africa. Sex Transm Dis 2015; 42: 43–47. [PubMed: 25504300]
23. Joseph-Davey D, Medina-Marino A, Mudau M, et al. Behavioral risk factors among HIV-infected pregnant women with a sexually transmitted infection in South Africa In: 9th International AIDS Society Conference on HIV Science, Paris, France, 23–26 July 2017, p.245 Geneva: International AIDS Society.
24. Cohen MS. Classical sexually transmitted diseases drive the spread of HIV-1: back to the future. J Infect Dis 2012; 206: 1–2. [PubMed: 22517911]
25. Mafokwane TM and Samie A. Prevalence of chlamydia among HIV positive and HIV negative patients in the Vhembe District as detected by real time PCR from urine samples. BMC Res Notes 2016; 9: 102. [PubMed: 26879379]
26. World Health Organisation. Guidelines for the treatment of *Chlamydia trachomatis* WHO Guidelines Approved by the Guidelines Review Committee. Geneva: WHO Press, 2016.
27. World Health Organisation. Guidelines for the treatment of *Neisseria gonorrhoeae* WHO Guidelines Approved by the Guidelines Review Committee. Geneva: WHO Press, 2016.
28. Guy R, Ward J, Wand H, et al. Coinfection with *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis*: a cross-sectional analysis of positivity and risk factors in remote Australian Aboriginal communities. Sex Transm Infect 2015; 91: 201–206. [PubMed: 25352691]
29. Forward KR. Risk of coinfection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in Nova Scotia. Can J Infect Dis Med Microbiol 2010; 21: e84–e86. [PubMed: 21629610]
30. Templeton DJ, Manokaran N and O'Connor CC. Prevalence and predictors of chlamydia co-infection among patients infected with *gonorrhoeae* at a sexual health clinic in Sydney. Sex Health 2012; 9: 392–394. [PubMed: 22877601]

31. Giuliano AR, Botha MH, Zeier M, et al. High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial. *J Acquir Immune Defic Syndr* 2015; 68: 227–235. [PubMed: 25415290]
32. Abbai NS, Wand H and Ramjee G. Sexually transmitted infections in women participating in a biomedical intervention trial in Durban: prevalence, coinfections, and risk factors. *J Sex Transm Dis* 2013; 2013: 358402. [PubMed: 26316957]
33. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. *J Infect Dis* 2001; 183: 206–212. [PubMed: 11120927]
34. Clouse K, Pettifor A, Shearer K, et al. Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. *Trop Med Int Health* 2013; 18: 451–456. [PubMed: 23374278]

Figure 1. Mono- and mixed-*Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* infections among HIV-infected women with STI co-infections in Tshwane District, South Africa.

HIV: human immunodeficiency virus; STI: sexually transmitted infection.

Table 1.

Socio-demographic characteristics of HIV-infected women tested for *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* in two healthcare facilities in Tshwane district, South Africa (n = 247).

Characteristic	n	%
Age (years), median (IQR)	30 (26–34)	
Level of education		
Below high school	138	56.1
High school or higher	108	43.9
Relationship with father of baby		
No relationship	7	2.8
Married	39	15.9
Steady partner living with me	82	33.3
Steady partner not living with me	118	48.0
Employment		
Employed full-time	62	25.2
Employed part-time	27	11.0
Self employed	11	4.5
Not employed	146	59.3
Sources of income ^a		
Social grant	98	39.7
Salary/wages	90	36.4
Business profit	24	9.7
Partner/spouse income	108	43.7
Children/family income	47	19.0
Monthly personal income		
< 1000 ZAR per month	98	39.8
1001–5000 ZAR per month	127	51.6
5001–10,000 ZAR per month	21	8.5
Gestational age (weeks), median (IQR)	17 (13–23)	

HIV: human immunodeficiency virus; IQR: interquartile range.

One participant had missing socio-demographic data.

^aSources of income are not mutually exclusive

Table 2.

Prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* among 247 HIV-infected pregnant women in two healthcare facilities in Tshwane district, South Africa.

	n	%	95% CI
Any STI (CT/NG/TV) infection	118	47.8	41.6–54.1
Any CT infection	91	36.8	31.0–43.1
Any NG infection	17	6.9	4.31–10.8
Any TV infection	59	23.9	18.9–29.6

CI: confidence interval; CT: *Chlamydia trachomatis*; HIV: human immunodeficiency virus; NG: *Neisseria gonorrhoeae*; STI: sexually transmitted infection; TV: *Trichomonas vaginalis*.

Table 3.

Prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* by clinical and socio-demographic characteristics of HIV-infected pregnant women in two healthcare facilities in Tshwane district, South Africa.

Characteristic	Total tested	Positive for CT		Positive for NG		Positive for TV		Positive for any infection	
		Row %	95% CI	Row %	95% CI	Row %	95% CI	Row %	95% CI
Age group									
< 25 years	42	61.9	46.3–75.4	16.7	8.06–31.3	28.6	16.8–44.1	66.7	51.0–79.3
25–35 years	168	32.1	25.5–39.6	4.8	2.39–9.28	22.0	16.4–29.0	43.5	36.1–51.1
>35 years	37	29.7	17.1–46.5	5.4	1.32–19.6	27.0	15.0–43.7	45.9	30.6–62.2
Level of education									
Below matric	138	36.2	28.6–44.6	9.4	5.52–15.6	27.5	20.7–35.6	51.4	43.1–59.7
Matric certificate and above	108	37.0	28.4–46.6	3.7	1.38–9.54	18.5	12.2–27.1	42.6	33.6–52.2
Relationship with father of baby									
No relationship	7	50.0	14.7–85.3	16.7	1.85–68.0	33.3	7.16–76.4	66.7	23.6–92.8
Married	39	23.1	12.3–39.0	2.6	0.35–16.6	12.8	5.35–27.7	28.2	16.2–44.4
Steady partner living with me	82	31.7	22.5–42.6	4.9	1.82–12.4	20.7	13.2–31.0	43.9	33.5–54.9
Steady partner not living with me	118	44.1	35.3–53.2	9.3	5.21–16.1	28.8	21.3–37.7	55.9	46.8–64.7
Employment status									
Employed full-time	62	29.0	19.0–41.6	4.8	1.55–14.1	21.0	12.5–33.0	35.5	24.5–48.2
Employed part-time	27	37.0	20.9–56.7	7.4	1.80–25.9	29.6	15.3–49.5	48.1	30.0–66.8
Self employed	11	27.3	8.48–60.3	0.0		9.1	1.13–46.6	36.4	13.5–67.6
Not employed	146	40.4	32.7–48.6	8.2	4.70–14.0	24.7	18.3–32.4	53.4	45.3–61.4
Income level									
< 1000 ZAR per month	98	43.9	34.3–53.9	11.2	6.29–19.2	27.6	19.6–37.3	58.2	48.2–67.6
1001–5000 ZAR per month	127	33.1	25.4–41.8	4.7	2.12–10.2	22.0	15.6–30.2	42.5	34.2–51.3
>5000 ZAR per month	21	23.8	10.0–46.8	0.0		14.3	4.52–37.0	28.6	13.1–51.5
Gestational age									
First trimester (1–12 weeks)	57	36.2	27.6–49.4	10.3	4.67–21.4	20.7	12.1–33.2	44.8	32.5–57.9
Second trimester (13–27 weeks)	161	34.5	27.6–42.2	5.5	2.85–10.2	24.8	18.8–32.1	47.3	39.7–55.0
Third trimester (28–34 weeks)	21	57.1	35.4–76.5	9.5	2.29–32.1	23.8	10.0–46.8	61.9	39.6–80.1
Gravidity									

Characteristic	Total tested	Positive for CT		Positive for NG		Positive for TV		Positive for any infection (95% CI)	
		Row %	95% CI	Row %	95% CI	Row %	95% CI	Row %	95% CI
1	27	48.1	30.0–66.8	11.1	3.52–29.9	29.6	15.3–49.5	59.3	39.9–76.2
2	80	35.0	25.3–46.1	3.8	1.2–11.1	23.8	15.6–34.4	43.8	33.2–54.9
3	75	37.3	27.1–48.9	8.0	3.60–16.8	20.0	12.4–30.7	52.0	40.7–63.1
>3	65	33.8	23.2–46.3	7.7	3.20–17.4	26.2	16.8–38.3	43.1	31.5–55.4
Last known CD4 cell count									
< 200	37	29.7	17.1–46.5	0.0		8.1	2.58–22.7	32.4	19.2–49.2
200–349	40	42.5	28.1–58.3	10.0	3.73–24.2	22.5	12.0–38.2	50.0	34.7–65.3
350–499	56	39.3	27.3–52.7	8.9	3.71–19.9	28.6	18.2–41.9	53.6	40.4–66.3
>500	61	32.8	22.1–45.6	6.6	2.45–16.4	31.1	20.7–43.9	47.5	35.3–60.1
Last known viral load									
Detectable	68	48.5	36.7–60.5	7.4	3.04–16.7	26.5	17.2–38.4	55.9	43.8–67.4
Undetectable	38	21.1	10.1–37.2	5.3	1.27–19.3	23.7	12.6–40.1	39.5	25.1–56.0

CI: confidence interval; CT: *Chlamydia trachomatis*; HIV: human immunodeficiency virus; NG: *Neisseria gonorrhoeae*; TV: *Trichomonas vaginalis*.

Table 4.

Prevalence of symptoms among HIV-infected women infected with *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* in two healthcare facilities in Tshwane district, South Africa.

	Overall N = 118		CT N = 91		NG N = 17		TV N = 59	
	Number symptomatic	% symptomatic	Number symptomatic	% symptomatic	Number symptomatic	% symptomatic	Number symptomatic	% symptomatic
Self-reported symptoms	28	23.7	27	29.7	8	47.1	16	27.1
Abnormal vaginal discharge	24	20.3	24	26.4	8	47.1	13	22.0
Increased pain during intercourse	5	4.2	5	5.5		5.9	3	5.3
Pain during urination	5	4.2	4	4.4		5.9	4	6.8
Vaginal bleeding	0	0.0	0	0.0	0	0.0	0	0.0
Clinician-observed signs	37	31.4	29	31.9	9	52.9	22	37.3
Abnormal vaginal discharge	37	31.4	29	31.9	9	52.9	22	37.3
Vaginal bleeding	0	0.0	0	0.0	0	0.0	0	0.0
Combined	49	41.5	41	45.1	11	64.7	30	50.9

CT: *Chlamydia trachomatis*; HIV: human immunodeficiency virus; NG: *Neisseria gonorrhoeae*; TV: *Trichomonas vaginalis*.

Table 5.

Prevalence of symptoms by socio-demographic and clinical characteristics among HIV-infected pregnant women co-infected with *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and/or *Trichomonas vaginalis* in two healthcare facilities in Tshwane District, South Africa.

Characteristic	Number infected with CT, NG or TV	n	%	Symptomatic			
				OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
Age group							
< 25 years	28	19	67.9	4.22 (1.71–10.4)	0.0012	6.01 (1.86–19.4)	0.003
25–35 years	73	26	35.6	0.53 (0.25–1.13)	0.0977		
>35 years	17	4	23.5	0.38 (0.12–1.26)	0.0936		
Level of education							
Below matric	71	26	36.6	0.58 (0.27–1.23)	0.1524		
Matric certificate and above	46	23	50.0		Ref		
Employment status							
Employed full-time	22	9	40.9	0.95 (0.37–2.44)	0.9183		
Employed part-time	13	7	53.9	1.72 (0.54–5.49)	0.3571		
Self employed	4	0	0.0				
Not employed	78	33	42.3	1.05 (0.48–2.30)	0.8945		
Income level							
< 1000 ZAR per month	57	25	43.9	1.17 (0.56–2.44)	0.6723		
1001–5000 ZAR per month	54	22	40.7	0.92 (0.44–1.92)	0.8170		
>5000 ZAR per month	6	2	33.3	0.68 (0.12–3.87)	0.6594		
Gestational age							
First trimester (1–12 weeks)	26	8	30.8	0.57 (0.22–1.44)	0.2222	0.24 (0.07–0.86)	0.028
Second trimester (13–27 weeks)	78	32	41.0	1.00 (0.46–2.18)	1.0000		
Third trimester (28–34 weeks)	13	8	61.5	2.56 (0.78–8.37)	0.1140		
Gravidity							
1	16	6	37.5	0.82 (0.28–2.44)	0.7241		
2	35	18	51.4	1.78 (0.80–3.95)	0.1579		
3	39	13	33.3	0.60 (0.27–1.33)	0.2014		
>3	28	12	42.9	1.07 (0.46–2.53)	0.8701		
Last known CD4 cell count							

Characteristic	Number infected with CT, NG or TV			Symptomatic		
	n	%	OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
< 200	4	33.3	0.60 (0.17–2.15)	0.4211		
200–349	11	55.0	1.77 (0.65–4.81)	0.2614		
350–499	9	30.0	0.41 (0.16–1.05)	0.0571		
>500	16	55.2	1.95 (0.80–4.76)	0.1410		
Last known viral load						
Detectable	38	44.7	0.82 (0.24–2.78)	0.754		
Undetectable	15	40.0		Ref		

CI: confidence interval; CT: *Chlamydia trachomatis*; HIV: human immunodeficiency virus; NG: *Neisseria gonorrhoeae*; OR: odds ratio; TV: *Trichomonas vaginalis*.